AVANIR Receives Nasdaq Staff Determination Letter (Business Wire via Yahoo! Finance)
ALISO VIEJO, Calif.----AVANIR Pharmaceuticals today announced that it has received a Staff Determination Letter from Nasdaq notifying the Company that it is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market pursuant to Marketplace Rule 4450.

Alkermes and Cephalon: Vivitrol's sales likely to be unaffected by FDA's warning (Pharmaceutical Business Review)
The FDA has warned of the risk of injection site reactions to Vivitrol, a once-monthly injection drug for the treatment of alcohol dependence. However, due to the considerable adverse health consequences related to alcohol dependence, along with the limited number of prescription drugs available, Datamonitor does not expect Vivitrol to experience a substantial downturn in sales.

Solei Systems, Inc. Announces Preliminary FDA Compliance of Its Patent Pending Light Therapy System (Marketwire via Yahoo! Finance)
Solei Systems, Inc. announced today that its patent pending liquid cooled "LED" phototherapy machine has met the preliminary FDA requirements. The Company has entered into an agreement with an FDA approved independent consulting and testing laboratory to conduct the remaining tests in order to obtain final 510(k) FDA Clearance, UL approval, CSA C22.2 #601.1, IEC 60601-1, IEC 60601-1-2, CENELEC ...